EN DE
Data-driven stock valuation

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) fair value: what the stock is really worth

We calculate from audited financials what NewAmsterdam Pharma Company N.V. Ordinary Shares is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Healthcare · US · Market cap $4.2B · ISIN NL00150012L7

At a glance

NP NewAmsterdam Pharma Company N.V. Ordinary Shares logo NewAmsterdam Pharma Company N.V. Ordinary Shares NAMS · US
Price$21.86
Fair Value$4.29
Upside−80.4%
Quality24/100

Below-average quality, and trading another 409% above our fair value of $4.29.

As of Aug 22, 2026, the fair value of NewAmsterdam Pharma Company N.V. Ordinary Shares is $4.29 per share against a price of $21.86, so the fair value sits 80% below the price. A model estimate from reported figures, not an analyst target.

!Weak Growth (revenue 3y −39.7 %/yr)
!Thin margins · 0.0% net margin
!negative free cash flow
!Trails peers (2/7)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
!Weak on future: 11 out of 100
Evidence: Low Range $2.83 to $5.36

Fair value as of: Aug 22, 2026

From 1 valuation models · updated 20 days ago

Share price −20.9% over the past month.

Watch NewAmsterdam Pharma Company N.V. Ordinary Shares for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case ($5.36). The favourable scenario is already priced in.
  • Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • A fairly wide model range ($2.83 to $5.36) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

$41.45 $5.98 Fair Value $4.29 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.

How to read this chart

60‑month range $5.98 – $41.45 · fair‑value band $2.83 – $5.36 · the $21.86 price screens above the $4.29 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) currently trades at $21.86, while our model-based Fair Value estimate is $4.29, implying the stock looks roughly 409.2% overvalued today. The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Trailing-twelve-month revenue stands at $22.6M. Revenue grew 2.1% year over year. It earns a return on equity of −29.5%. The balance sheet holds a net cash position of $490M. Fundamentals as of Aug 22, 2026

Scenario range: $2.83 (bear) to $5.36 (bull), the price of $21.86 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 48% below its 52-week high and 24% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −80%, NAMS screens richer than that median.

Fair Value models

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) best evidence $2.92 $3.92 $5.85 51
All 1 models by family
Asset-Based
NCAV (Graham) best evidence $2.92 $3.92 $5.85 51

Notify me when NAMS reaches fair value

Put NAMS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

EPS (TTM) $−1.75
Return on equity −29.5% TTM
Return on assets (EBIT) −30.9% avg 5y
Operating margin −1,922% TTM
Revenue (TTM) $22.6M TTM
Revenue growth (YoY) +2.1% 3y avg −39.7%
More key figures
Balance sheet & cash flow
Free cash flow −$148M FY2025
Net cash $490M FY2025

Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 24/100

Of which business quality 31 · Market factors (momentum, volatility) 27

Profitability 1
Margins and returns on capital today
Quality Growth 30
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 44
Disciplined investing over empire-building
Low Volatility 54
Calm price path (market factor)
Momentum 18
Price trend over the last 3–12 months (market factor)
52W Momentum 10
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

Full company description

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

NewAmsterdam Pharma Company N.V. Ordinary Shares reported revenue of $22.5M in FY2025 versus $0 in FY2021. Reported net income was −$204M in FY2025.

Growth Quality 0/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
$22.5M
Latest YoY
−50.6%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−39.7%
EBIT margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3.5% (2022) → −1,002.9% (2025)
Value creation/yr ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Revenue
FY21 $0
FY22 $103M
FY23 $14.1M
FY24 $45.6M
FY25 $22.5M
Net income
FY21 −$41.8M
FY22 −$22.6M
FY23 −$177M
FY24 −$242M
FY25 −$204M

NAMS screens 409% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NewAmsterdam Pharma Company N.V. Ordinary Shares · Fair Value
$4.29 −409%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "NewAmsterdam Pharma Company N.V. Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/NAMS

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Biotechnology · 635 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −80% · Bottom 25%
Profitability
Return on assets −17% · Below median
Net margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 2% · Above median

Valuation Multiples vs Biotechnology median · lower = cheaper

P/B 6.14× · Priciest 25%

Context: sector, industry, market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE11 · sector 0
PAST0 · sector 0
HEALTH0 · sector 98
DIVIDEND0 · sector 27

VALUE 0: the price sits above our fair-value range.

Insider activity: 42/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $546.12 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $827.72 $594.40 −28%
argenx SE ARGX €877.60 €292.84 −67%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,452,000 KRW 1,055,793 KRW −27%
CSL Limited CSL A$174.50 A$141.68 −19%
Alnylam Pharmaceuticals, Inc ALNY $228.61 $51.70 −77%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BioNTech SE BNTX $103.76 $45.70 −56%

Compare NewAmsterdam Pharma Company N.V. Ordinary Shares with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) overvalued or undervalued?
As of Aug 22, 2026, our model estimates a fair value of $4.29 versus a price of $21.86, about −80% upside (overvalued).
What is the fair value of NAMS?
Our model-based fair value for NewAmsterdam Pharma Company N.V. Ordinary Shares is $4.29 (as of Aug 22, 2026), built from audited fundamentals. The current price: $21.86.
What is the quality score of NAMS?
NewAmsterdam Pharma Company N.V. Ordinary Shares has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)?
Our model-based price target is the fair value of $4.29 (as of Aug 22, 2026) from 1 valuation models. Cautious scenario $2.83, optimistic scenario $5.36. It is a calculation from audited fundamentals, not an analyst target.
What is the NewAmsterdam Pharma Company N.V. Ordinary Shares stock forecast for 2026?
Our models put fair value at $4.29, about −80% upside versus a price of $21.86 (overvalued). Cautious scenario $2.83, optimistic scenario $5.36. The calculation is refreshed regularly with new filings.
What is the revenue of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)?
NewAmsterdam Pharma Company N.V. Ordinary Shares reported trailing-twelve-month revenue of about $22.6M (latest available figure, as of Aug 22, 2026).
What is the net profit margin of NAMS?
The net profit margin of NewAmsterdam Pharma Company N.V. Ordinary Shares is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.
What is the intrinsic value of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NewAmsterdam Pharma Company N.V. Ordinary Shares it is $4.29 per share (as of Aug 22, 2026), against a price of $21.86. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is NewAmsterdam Pharma Company N.V. Ordinary Shares stock overvalued or undervalued in 2026?
As of Aug 22, 2026, NAMS trades above its calculated fair value: price $21.86, fair value $4.29, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NAMS?
No. The price is what the market pays today ($21.86); the fair value is what the company's own numbers justify ($4.29). For NewAmsterdam Pharma Company N.V. Ordinary Shares the two are $17.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is NewAmsterdam Pharma Company N.V. Ordinary Shares worth?
The market values NewAmsterdam Pharma Company N.V. Ordinary Shares at about $4.2B (market capitalisation, as of Aug 22, 2026). Per share that is $21.86; our models calculate a fair value of $4.29 per share.
What do the bullish and bearish scenarios say about NAMS?
Our models span a range for NewAmsterdam Pharma Company N.V. Ordinary Shares: cautious scenario $2.83, base $4.29, optimistic $5.36 per share (as of Aug 22, 2026, price $21.86). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)?
Balance-sheet figures for NewAmsterdam Pharma Company N.V. Ordinary Shares (as of Aug 22, 2026): return on equity −29.5%. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is NAMS from its 52-week high?
NewAmsterdam Pharma Company N.V. Ordinary Shares trades at $21.86, about 48% below its 52-week high of $42.21 and 24% above the low of $17.63 (as of Aug 22, 2026). Distance from the high says nothing about value: that is what the fair value of $4.29 is for.
Which stocks are comparable to NewAmsterdam Pharma Company N.V. Ordinary Shares?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NewAmsterdam Pharma Company N.V. Ordinary Shares stock attractive at the current price?
The data as of Aug 22, 2026: price $21.86, calculated fair value $4.29 (−80%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NAMS calculated?
We run NewAmsterdam Pharma Company N.V. Ordinary Shares through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.29, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 32.6 % above its aggregate fair value. NewAmsterdam Pharma Company N.V. Ordinary Shares itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on <a href="/is-it-worth-investing-now/">is it worth investing now</a>.
Free · no account needed

Watch NewAmsterdam Pharma Company N.V. Ordinary Shares in the live analysis

One click puts NewAmsterdam Pharma Company N.V. Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.